The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Tanner Michael Johanns
No Relationships to Disclose
 
Niharika B. Mettu
Honoraria - Alimera Sciences (I); Notal Vision (I)
Consulting or Advisory Role - Eclipse Life Sciences (I); Eyedea Bio (I); Iveric Bio (I); Merck (I); Protagonist Therapeutics (I); Pulsar Life Sciences (I)
Research Funding - Actuate Therapeutics (Inst); Adanate (Inst); Amgen (Inst); Aravive (Inst); BioMed Valley Discoveries (Inst); Compass Therapeutics (Inst); Leap Therapeutics; Merck (Inst); Mereo BioPharma (Inst); Nucana (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Syros Pharmaceuticals (Inst)
 
Seth D Rosen
Employment - Hematology Oncology Associates of the Treasure Coast
Stock and Other Ownership Interests - Abbvie; Amgen; Amgen; GlaxoSmithKline; Lilly; Merck; Pfizer
 
William Jeffery Edenfield
No Relationships to Disclose
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - BMS; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Aime Giorlando
Employment - IQ IA
Consulting or Advisory Role - IQVIA
 
Thomas Schuetz
Employment - Compass Therapeutics
Leadership - Compass Therapeutics
Stock and Other Ownership Interests - Compass Therapeutics
Patents, Royalties, Other Intellectual Property - Compass Therapeutics
Travel, Accommodations, Expenses - Compass Therapeutics